This is a 45-minute MOC Section 3 accredited eCME program for Canadian HCPs. This program is designed to provide practical, evidence-based insights into the diagnosis and management of generalized pustular psoriasis (GPP), a rare, chronic skin condition with potentially life-threatening flares. Using a patient case study, this program will examine the clinical presentation and chronic nature of GPP, including its lifelong physical, emotional, and psychosocial impacts. The role of the interleukin-36 (IL-36) receptor pathway in disease pathogenesis, and strategies for managing and preventing GPP flares will also be explored. Particular emphasis will be placed on spesolimab, a recently Health Canada-approved, first-in-class IL-36 receptor antagonist designed specifically for GPP treatment.<\/p>\n
This program has received financial support from Boehringer Ingelheim in the form of an unrestricted educational grant.<\/p>","protected":false},"excerpt":{"rendered":"
This is a 45-minute MOC Section 3 accredited eCME program for Canadian HCPs. This program is designed to provide practical, evidence-based insights into the diagnosis and management of generalized pustular psoriasis (GPP), a rare, chronic skin condition with potentially life-threatening flares. Using a patient case study, this program will examine the clinical presentation and chronic […]<\/p>\n","protected":false},"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false},"product_brand":[],"product_cat":[],"product_tag":[],"class_list":{"0":"post-48328","1":"product","2":"type-product","3":"status-publish","6":"first","7":"instock","8":"downloadable","9":"virtual","10":"taxable","11":"purchasable","12":"product-type-simple"},"acf":[],"yoast_head":"\n